CLEC10A and neoplasm: The focal point remains on innate immune system cells, specifically those expressing glycan-binding receptors like CD301 (MGL) [50], Siglec-4, -5, -14, and -15 [51], and potentially other receptors selectively interacting with tumor O-glycans.